BridgeBio Pharma, Inc. (BIT:1BBIO)

Italy · Delayed Price · Currency is EUR

62.60

-1.68 (-2.61%)

At close: Dec 5, 2025

Market Cap	12.20B
Revenue (ttm)	301.53M
Net Income (ttm)	-679.38M
Shares Out	n/a
EPS (ttm)	-3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	13
Open	n/a
Previous Close	64.28
Day's Range	n/a
52-Week Range	28.90 - 64.28
Beta	n/a
RSI	66.31
Earnings Date	Feb 20, 2026

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Employees 730

Stock Exchange Borsa Italiana

Ticker Symbol 1BBIO

Full Company Profile

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.